These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 36102236)
1. Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial. Dransfield MT; Criner GJ; Halpin DMG; Han MK; Hartley B; Kalhan R; Lange P; Lipson DA; Martinez FJ; Midwinter D; Singh D; Wise R; Kunisaki KM J Am Heart Assoc; 2022 Sep; 11(18):e024350. PubMed ID: 36102236 [TBL] [Abstract][Full Text] [Related]
2. Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan. Matsunaga K; Yoshida Y; Makita N; Nishida K; Rhodes K; Nordon C Adv Ther; 2024 Aug; 41(8):3362-3377. PubMed ID: 38976123 [TBL] [Abstract][Full Text] [Related]
3. Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study. Graul EL; Nordon C; Rhodes K; Marshall J; Menon S; Kallis C; Ioannides AE; Whittaker HR; Peters NS; Quint JK Am J Respir Crit Care Med; 2024 Apr; 209(8):960-972. PubMed ID: 38127850 [No Abstract] [Full Text] [Related]
4. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands. Swart KMA; Baak BN; Lemmens L; Penning-van Beest FJA; Bengtsson C; Lobier M; Hoti F; Vojinovic D; van Burk L; Rhodes K; Garbe E; Herings RMC; Nordon C; Simons SO Respir Res; 2023 Nov; 24(1):293. PubMed ID: 37990197 [TBL] [Abstract][Full Text] [Related]
5. The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. Wise RA; Chapman KR; Scirica BM; Daoud SZ; Lythgoe D; Garcia-Gil E Int J Chron Obstruct Pulmon Dis; 2021; 16():689-699. PubMed ID: 33776428 [TBL] [Abstract][Full Text] [Related]
6. Chronic Obstructive Pulmonary Disease Exacerbations Increase the Risk of Subsequent Cardiovascular Events: A Longitudinal Analysis of the COPDGene Study. Yang HM; Ryu MH; Carey VJ; Kinney GL; Hokanson JE; Dransfield MT; Hersh CP; Silverman EK; J Am Heart Assoc; 2024 Jun; 13(11):e033882. PubMed ID: 38818936 [TBL] [Abstract][Full Text] [Related]
7. Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study. Daniels K; Lanes S; Tave A; Pollack MF; Mannino DM; Criner G; Neikirk A; Rhodes K; Feigler N; Nordon C Int J Chron Obstruct Pulmon Dis; 2024; 19():225-241. PubMed ID: 38259591 [TBL] [Abstract][Full Text] [Related]
16. Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors. So JY; Zhao H; Voelker H; Reed RM; Sin D; Marchetti N; Criner GJ Ann Am Thorac Soc; 2018 Nov; 15(11):1296-1303. PubMed ID: 30063372 [TBL] [Abstract][Full Text] [Related]
17. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829 [TBL] [Abstract][Full Text] [Related]
18. Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany. Vogelmeier CF; Rhodes K; Garbe E; Abram M; Halbach M; Müllerová H; Kossack N; Timpel P; Kolb N; Nordon C BMJ Open Respir Res; 2024 Mar; 11(1):. PubMed ID: 38555102 [TBL] [Abstract][Full Text] [Related]
19. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Wedzicha JA; Singh D; Tsiligianni I; Jenkins C; Fucile S; Fogel R; Shen S; Goyal P; Mezzi K; Kostikas K Respir Res; 2019 Jan; 20(1):4. PubMed ID: 30621717 [TBL] [Abstract][Full Text] [Related]
20. Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort. Frantzi N; Nguyen XP; Herr C; Alter P; Söhler S; Soriano D; Watz H; Waschki B; Trinkmann F; Eichenlaub M; Trudzinski FC; Michels-Zetsche JD; Omlor A; Seiler F; Moneke I; Biertz F; Rohde G; Stolz D; Welte T; Kauczor HU; Kahnert K; Jörres RA; Vogelmeier CF; Bals R; Fähndrich S; Respir Res; 2024 May; 25(1):207. PubMed ID: 38750572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]